Improvement of renal outcomes with sodium-glucose cotransporter-2 (SGLT2) inhibitors
Abstract
Published in 2015, the EMPA-REG cardiovascular outcome trial (CVOT) investigated empagliflozin in patients with type 2 diabetes (T2D). This agent promotes glycosuria by inhibiting Sodium-Glucose Cotransporter-2 (SGLT2), that is expressed in the first segment of the renal proximal tubule. The study aimed to provide evidence for the drug's cardiovascular (CV) safety, as required by regulatory authorities for newly developed glucose lowering agents (GLA)s. Surprisingly, besides being safe, empagliflozin was effective in reducing CV morbidity and mortality as well as improving renal outcomes, compared with placebo. EMPA-REG was followed by subsequent CVOTs that demonstrated the value of additional SGLT2 inhibitors to improve CV and renal outcomes in different populations: patients with mostly normal kidney function (DECLARE-TIMI 58), with early stage chronic kidney disease (CKD) (EMPA-REG and CANVAS) and patients with advanced proteinuric CKD (CREDENCE). Intriguingly, recent reports demonstrated that SGLT2 inhibitors improve CV and renal outcomes in high-risk populations with and without T2D: patients with CKD (DAPA-CKD) or with heart failure and reduced ejection fraction (HFrEF; DAPA-HF and EMPEROR-Reduced). This review focuses on the renal aspect of the large trials investigating SGLT2 inhibitors. We will discuss the populations investigated, the defined renal outcomes and their hierarchy within the trials - all used as a framework to interpret the renal findings and their…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.